Related by context. All words. (Click for frequent words.) 69 statistically significant reduction 67 clinically meaningful improvements 67 clinically meaningful improvement 65 statistically significant 64 primary endpoint 64 secondary endpoints 63 primary efficacy endpoint 63 statistically significant differences 63 demonstrated statistically significant 63 placebo 62 Secondary endpoints include 62 secondary endpoint 62 Secondary endpoints included 61 desvenlafaxine succinate 61 achieved statistical significance 60 p = #.# [002] 60 placebo p = 60 CIMZIA TM certolizumab pegol 59 Secondary endpoints 59 evaluable 59 median PFS 59 placebo p 59 Rating Scale MADRS 58 Psoriasis Area 58 clinically meaningful 58 p = #.# [004] 58 mg dose 58 plus methotrexate 58 evaluable patients 58 CIMZIA ™ 58 tapentadol ER 57 viral kinetics 57 primary endpoints 57 secondary efficacy endpoints 57 #mg/day [001] 57 etanercept 57 rotigotine 57 statistically significant p 57 mg kg dose 57 mg QD 57 mcg QD 57 p = 57 oxycodone CR 57 MADRS score 56 P = .# 56 mcg kg 56 CR CRu 56 nasal symptom 56 Montgomery Asberg Depression 56 MADRS 56 elagolix 56 Scale EDSS 56 tumor shrinkage 56 CSBM 56 8mg/kg 56 FOLFOX4 56 PASI scores 56 clinically meaningful reductions 56 Negative Syndrome 56 free survival PFS 56 tumor progression TTP 55 Primary endpoints 55 CIMZIA TM 55 patients evaluable 55 progression TTP 55 tiotropium 55 tipranavir r 55 secondary efficacy endpoint 55 docetaxel 55 analgesic efficacy 55 NLX P# 55 n = 55 achieve statistical significance 55 ribavirin RBV 55 prospectively defined 55 HDRS 55 timepoint 55 achieved ACR# 55 ACR# response 55 mg BID 55 mg kg 55 UPDRS motor 55 retinal thickness 55 #mg BID [001] 54 Montgomery Åsberg Depression 54 spontaneous bowel movements 54 quetiapine XR 54 plus ribavirin 54 annualized relapse 54 mcg BID 54 mucosal healing 54 ADCS ADL 54 efficacy endpoints 54 lispro 54 prespecified 54 FFNS 54 teriflunomide 54 Timed Walk 54 Unified Parkinson Disease 54 statistically significant superiority 54 Brief Psychiatric 54 UPDRS 54 APTIVUS r 54 intermittent dosing 54 achieving PASI 54 Scale PANSS 54 demonstrated clinically meaningful 54 partial remissions 54 VcMP 54 FEV1 54 PANSS 54 reach statistical significance 54 IPSS 54 mg/m2 dose 54 #mg BID [003] 54 Kaplan Meier analysis 54 RECIST criteria 54 non inferiority 54 phonophobia 54 serum phosphorus 54 randomized 54 rapid virologic response 54 symptom severity 53 HbA1c levels 53 VELCADE melphalan 53 undetectable HBV DNA 53 YMRS 53 ADCS CGIC 53 active comparator 53 clinically relevant 53 virologic response 53 monotherapy 53 plus gemcitabine 53 plus dexamethasone 53 Neuropsychiatric Inventory NPI 53 adjunctive placebo 53 Free Survival PFS 53 #mg QD [001] 53 insulin detemir 53 plus prednisone 53 cytogenetic response 53 composite endpoint 53 neurologic progression 53 undetectable HCV RNA 53 Apidra ® 53 mg qd 53 adalimumab 53 subscales 53 % CI #.#-#.# [003] 53 CNS LS 53 #mg QD [002] 53 febuxostat 53 moderate renal impairment 53 complete cytogenetic 53 statistically significant efficacy 53 5-FU/LV 53 HBeAg positive patients 53 endoscopic remission 53 Response Evaluation Criteria 53 salmeterol fluticasone 53 pCR 53 statistical significance 53 CRp 53 dose limiting toxicities 53 ACTEMRA TM 53 Global Impression 53 Index CDAI 53 WOMAC pain 53 nausea photophobia 53 glycosylated hemoglobin 53 4mg/kg 53 hemoglobin A1c HbA1c 53 ABC/3TC 53 mg ustekinumab 53 PEG IFN 53 gout flares 53 GERD symptom 53 placebo controlled clinical 53 statistically significant p = 53 LEXIVA r 53 GOUT 53 peginterferon alfa 2a 53 HBeAg seroconversion 53 bortezomib refractory 53 MAP# 53 pharmacodynamic 53 incontinence episodes 53 primary efficacy endpoints 53 SVR# 53 Alzheimer Disease Assessment 53 highly emetogenic 53 fasting plasma glucose 53 CR nPR 53 RECIST Response Evaluation Criteria 53 baseline PASI 53 chlorambucil 53 mg TID 52 DAS# CRP 52 certolizumab 52 methotrexate monotherapy 52 #mg dose [003] 52 zonisamide SR 52 ADAS Cog 52 octreotide 52 maximal tolerated 52 PREZISTA r 52 SSRI citalopram 52 FOLPI 52 sustained virologic response 52 QoL 52 octreotide LAR 52 IFN α 52 attain statistical significance 52 viral kinetic 52 posttreatment 52 ADAS cog 52 inflammatory lesions 52 laboratory abnormalities 52 blind placebo 52 RAPAFLO R 52 Scale cognitive subscale 52 CCyR 52 rosuvastatin #mg 52 SGRQ 52 p = .# [002] 52 QTcF 52 TLUS 52 fosbretabulin 52 intraocular inflammation 52 HBeAg negative patients 52 surrogate endpoint 52 serologically active SLE 52 achieved PASI 52 FOLFOX 52 randomized #:#:# 52 biochemical relapse 52 pegylated interferon alfa 2b 52 doxorubicin docetaxel 52 pharmacodynamic PD 52 insulin glargine 52 plasma HCV RNA 52 lopinavir r arm 52 LANTUS R 52 mcg Albuferon 52 ≥ 52 Health Assessment Questionnaire 52 depressive symptoms 52 abdominal pain abdominal discomfort 52 VAPRISOL 52 comparator arm 52 WOMAC 52 PANSS scores 52 exacerbations 52 tumor regression 52 nab paclitaxel 52 μg kg 52 NPH insulin 52 achieve sustained virologic 52 pramipexole 52 log# 52 relapsing multiple sclerosis 52 lopinavir r 52 Visual Analog Scale 52 mg RDEA# 52 nonsignificant 52 atazanavir ritonavir 52 NIH CPSI 52 morphometric vertebral fractures 52 bosentan 52 colesevelam HCl 52 LVEF 52 fasting plasma glucose FPG 52 QTc 52 AUC0 52 #mg/m# [001] 52 HCV RESPOND 2 52 pharmacokinetics PK 52 intradermal injections 52 Score IPSS 52 locoregional disease 52 limiting toxicity 52 estramustine 52 KRN# 52 Crohn Disease Activity 52 CANCIDAS 52 pharmacodynamic effects 52 #mg BID [002] 51 degarelix 51 PSA nadir 51 Severity Index PASI 51 LEVADEX 51 FOLFIRI 51 #mg/kg [002] 51 Efficacy 51 log# IU mL 51 PANSS total 51 Flu Cy 51 non menstrual pelvic 51 inhaled iloprost 51 complete remissions 51 HAM D# 51 elevated creatinine 51 crizotinib PF # 51 nodular partial response 51 baminercept 51 Traficet EN 51 dexamethasone 51 rhinoconjunctivitis 51 HbA1c 51 #mg/day [002] 51 NIHSS 51 Median progression 51 mitoxantrone 51 IRLS 51 stage IIIb IV 51 oral rivaroxaban 51 postoperatively 51 plasma leptin 51 efficacy endpoint 51 quetiapine 51 RoACTEMRA 51 nadolol 51 dapagliflozin plus 51 p = NS 51 receiving golimumab 51 MoxDuo TM IR 51 serum urate 51 melphalan prednisone 51 prednisone prednisolone plus 51 dacarbazine chemotherapy 51 administered subcutaneously 51 DAS# remission 51 antipsychotic efficacy 51 TEAEs 51 Pegasys ® 51 IOP lowering 51 ULORIC 51 NYHA functional class 51 ritonavir boosted 51 noninferiority 51 Pred Forte 51 HAQ DI 51 dose dependently 51 seroprotection 51 dexamethasone Decadron 51 TDF FTC 51 mesalamine granules 51 HCV RNA 51 Expanded Disability Status 51 fluticasone salmeterol 51 tolterodine ER 51 mg d 51 leuprorelin 51 relapsed MM 51 achieved CCyR 51 OADs 51 Cmax 51 placebo fluoxetine 51 QTc prolongation 51 tolerability 51 detectable HCV RNA 51 GLIADEL R Wafer 51 eosinophilic asthma 51 baseline HbA1c 51 ACR# responses 51 plus MTX 51 bevacizumab 51 Lucentis monotherapy 51 rimonabant #mg 51 ibandronate 51 elevated ALT 51 severe hypoglycemic 51 infliximab monotherapy 51 glycosylated hemoglobin HbA1c 51 HAMD 51 fosamprenavir 51 Fibromyalgia Impact Questionnaire 51 peg IFN 51 treatment emergent adverse 51 PEGylated anti 51 remission CR 51 serum concentrations 51 subcutaneous injections 51 unresectable HCC 51 fluoxetine 51 IFN alfa 51 venlafaxine XR 51 MCyR 51 Elitek 51 Secondary efficacy endpoints 51 QD dosing 51 alicaforsen enema 51 Solid Tumors criteria 50 dose proportionality 50 Folfox 50 pioglitazone 50 sustained virological response 50 solifenacin 50 systolic BP 50 oblimersen 50 adefovir 50 pegylated interferon peg IFN 50 ascending doses 50 ug kg 50 dosing cohorts 50 ACR# [002] 50 PEG Intron 50 ALIMTA cisplatin 50 EDSS 50 heavily pretreated 50 BoNTA 50 peginterferon alfa 2b 50 R# #mg BID 50 #mg/m# [002] 50 Pegasys plus Copegus 50 null responders 50 Persistent Sleep 50 sUA 50 diameter stenosis 50 DLTs 50 #mg dose [001] 50 tertile 50 timepoints 50 REYATAZ r 50 virological response 50 abacavir lamivudine 50 tumor regressions 50 infliximab 50 low dose Iluvien 50 CDAI 50 severe exacerbations 50 imatinib therapy 50 bupivacaine 50 mcg albinterferon alfa 2b 50 ATACAND 50 abatacept 50 pregabalin 50 REYATAZ r arm 50 Pharmacokinetic parameters 50 laxation 50 sunitinib 50 transaminase elevations 50 placebo controlled 50 GSK# [001] 50 μmol L 50 triamcinolone 50 somatostatin analog 50 randomized controlled 50 1mg dose 50 HIV RNA 50 urate lowering therapy 50 pegylated liposomal doxorubicin 50 INC# 50 complete cytogenetic response 50 urate lowering 50 basal bolus regimen 50 dose titration 50 relapsed myeloma 50 lumbar spine BMD 50 International Prostate Symptom 50 ataluren 50 lanthanum carbonate 50 discontinuations due 50 6MWD 50 postintervention 50 clodronate 50 L PPDS 50 thromboembolic events 50 nonresponders 50 IBDQ 50 ADHD RS 50 Zometa hazard 50 HBeAg 50 tolvaptan 50 INCB# [003] 50 tamsulosin 50 glycated hemoglobin levels 50 peginterferon alfa 2a #KD 50 methotrexate MTX 50 Androxal TM 50 plasma pharmacokinetics 50 budesonide pMDI 50 everolimus eluting stents 50 mapatumumab 50 tolerability profile 50 carboplatin paclitaxel 50 virologic failure 50 posaconazole 50 placebo dexamethasone 50 oral diclofenac 50 undetectable viral load 50 bronchodilation 50 serum antibody 50 icatibant 50 OAB symptoms 50 subscale scores 50 Solid Tumors 50 evaluable subjects 50 hour bronchodilation 50 Target Lesion Revascularization TLR 50 ALVESCO 50 aspartate aminotransferase AST 50 interferon alfa 50 nondiabetic patients 50 Navelbine 50 ropivacaine 50 bronchodilatory 50 Monotherapy 50 pemetrexed 50 CI -#.# 50 febrile neutropenia 50 urinary N telopeptide 50 GAMMAGARD 50 oral FTY# 50 pomalidomide 50 azacitidine 50 nonrandomized 50 ALT normalization 50 randomized blinded 50 copies mL 50 evaluating tivozanib 50 glycosylated hemoglobin levels 49 response CCyR 49 antitumor activity 49 unfractionated heparin UFH 49 favorable pharmacokinetic profile 49 liver histology 49 #mg doses [002] 49 pegylated interferon alpha 49 Solid Tumours 49 oral prednisolone 49 pharmacokinetic equivalence 49 Solid Tumors RECIST 49 DMARD 49 CLARITY study 49 alemtuzumab treated 49 Engerix B 49 goserelin 49 Linagliptin 49 iniparib 49 sirolimus eluting stents 49 trough FEV1 49 Doxil ® 49 depressive symptom 49 glufosfamide 49 LPV r 49 mitoxantrone plus 49 inactive placebo 49 BARACLUDE r 49 Pharmacokinetic 49 glucose lowering 49 double blinded randomized 49 baseline A1C 49 Pharmacokinetics PK 49 AUA Symptom Score 49 relapsed MCL 49 Pain Intensity 49 Score DAS 49 fluoropyrimidine 49 HOMA IR 49 dacarbazine 49 Adalimumab 49 binary restenosis 49 highest tertile 49 dyspnea 49 insulin lispro 49 IU ml 49 AIR CF2 49 paricalcitol 49 subcutaneously administered 49 FOLFOX6 49 statin monotherapy 49 intracoronary 49 plus COPEGUS 49 ACR Pedi 49 hypoglycemic events 49 infarct size 49 SBMs 49 ketorolac 49 ARCALYST ® 49 placebo controlled clinical trials 49 virologic breakthrough 49 PCWP 49 State Examination MMSE 49 adenoma recurrence 49 BPH symptoms 49 lowest tertile 49 trials RCTs 49 EQ 5D 49 mCRC patients 49 temsirolimus 49 transaminases 49 weekly subcutaneous injections 49 tipranavir 49 nmol L 49 mg kg BID 49 intravesical 49 ACTEMRA 49 imetelstat 49 5mg/kg 49 Phase 2b study 49 serum phosphorous 49 EURIDIS 49 univariate analysis 49 calcineurin inhibitor 49 paliperidone ER 49 saline placebo 49 ispinesib administered 49 randomized placebo controlled 49 ARB telmisartan 49 Lantus R 49 subscore 49 RLAI 49 metastatic CRC 49 lymphopenia 49 multicenter randomized 49 antiretroviral naive 49 hyperphenylalaninemia HPA due 49 dosing cohort 49 hypogonadal men 49 BARACLUDE ® 49 events AEs 49 decitabine 49 Aptivus ® 49 clinically meaningful differences 49 hematologic toxicity 49 % Confidence Interval 49 DOXIL 49 relapsed CLL 49 HbA 1C 49 lacosamide 49 disease progression 49 Prosaptide 49 log# reduction 49 Score TOS 49 Pharmacokinetic studies 49 CC genotype 49 LATUDA 49 Partial Response 49 QIDS SR 49 favorable tolerability 49 biochemical recurrence 49 % CI #.#-#.# [007] 49 mg p = 49 olanzapine 49 serologically active patients 49 bolus injection 49 tegaserod 49 safinamide 49 -#.# log# copies mL 49 aripiprazole 49 hypercalcemia 49 microgram kg 49 RLS symptoms 49 remission induction 49 mg Proellex 49 Durezol 49 double blinded placebo 49 oral antidiabetic medication 49 Adverse events 49 IELT 49 HbA1C 49 azathioprine 49 PREZISTA r arm 49 Ceplene/IL-2 49 mITT population 49 + PH# 49 EDSS scores 49 histologic 49 anemia hemoglobin 49 MabCampath 49 plasma concentrations 49 vidofludimus 49 CSBMs 49 Scale CNS 49 recurrent glioblastoma multiforme 49 HbA 1c 49 IBS symptoms 49 plus OBT 49 TAXOTERE R 49 Fasting plasma glucose 49 glycated hemoglobin HbA1c 49 HRQL 49 Raptiva r 49 darunavir r 49 NEVO ™ 49 MACCE 49 dose cohort 49 miconazole 49 vasomotor symptoms 49 pain palliation 49 NOXAFIL Oral Suspension 49 squamous histology 49 AZILECT 49 citalopram 49 prespecified secondary 49 Insulin PH# 49 Taxotere ® 49 Subgroup analysis 49 Amrubicin 49 steroid dexamethasone 49 neutropaenia 49 MMSE score 49 ribavirin USP 49 Inventory BPI 49 peginterferon alpha 2a 49 intravitreal injection 49 postoperative ileus POI 49 tiotropium bromide 48 iPTH 48 ZP PTH 48 CINQUIL 48 demonstrated antitumor activity 48 headache nasopharyngitis 48 postdose 48 diabetic neuropathic pain 48 HIV HCV coinfected 48 lung metastases 48 blood Phe 48 pg ml 48 serum urate levels 48 Median PFS 48 epoetin alpha 48 3mg/kg 48 pharmacokinetic characteristics 48 μg 48 conjunctival hyperemia 48 eplerenone 48 GI motility 48 O PPDS 48 oral olanzapine 48 intravascular hemolysis 48 multicenter randomized double 48 ‰ ¥ 48 potent antiviral 48 methacholine challenge 48 CIPN 48 cEVR 48 donepezil 48 splenectomized patients 48 IIIa inhibitor 48 Score DAS# 48 EDSS score 48 BENICAR 48 virologic 48 erythema 48 unblinded 48 clomipramine 48 apremilast 48 recurrent GBM 48 refractory NSCLC 48 Phase 2a trial 48 fluorouracil 48 FOLFOX4 alone 48 briakinumab 48 DLQI 48 insulin degludec 48 mg administered orally 48 nighttime awakenings 48 mTSS 48 plus prednisone prednisolone 48 TNSS 48 tryptophan depletion 48 Rating Scale UPDRS 48 EMBLEM TM 48 IR prednisone 48 oral Hycamtin 48 prospectively randomized 48 dose colchicine 48 chemoradiotherapy 48 p ≤ 48 PROMACTA 48 SCIg 48 iloprost 48 low dose dexamethasone 48 symptomatic VTE 48 EDEMA3 trial 48 certolizumab pegol 48 lipid parameters 48 hematological toxicity 48 pharmacodynamic profiles 48 chemoradiation therapy 48 corticosteroid dose 48 KAPIDEX 48 escitalopram 48 STELARA 48 TMC# r 48 irbesartan 48 randomized clinical 48 interferon alfa 2b 48 AGILECT R 48 peg interferon 48 peginterferon 48 tocilizumab 48 FOLPI regimen 48 DAS# [002] 48 prospectively stratified 48 TACE 48 serum cortisol 48 AVOREN 48 satraplatin Phase 48 subscores 48 trastuzumab Herceptin ® 48 VaD 48 proteinuria 48 double blind placebo 48 gastrointestinal toxicities 48 Capesaris 48 HbA1C levels 48 HRQOL 48 risperidone 48 Peg IFN 48 pertuzumab 48 bardoxolone methyl 48 BEACOPP 48 preoperative 48 corrected QT interval 48 antiviral activity 48 microbiological eradication 48 metastatic HRPC 48 cabazitaxel 48 posttest 48 sumatriptan naproxen sodium 48 pegylated interferon 48 darunavir ritonavir 48 #.#mg/dL 48 multivariable analysis 48 alfuzosin 48 milatuzumab 48 Darusentan 48 serum phosphate levels 48 mcg mL 48 plasma uric acid 48 Ophena TM 48 apnea hypopnea index 48 EDEMA4 trial 48 COPAXONE R 48 posttransplant 48 MARINOL R 48 rimonabant #mg/day 48 HBeAg positive 48 extrapyramidal symptoms 48 confirmed CCyR 48 FOLFIRI alone 48 mg Lucentis 48 standard chemotherapy regimen 48 bronchial hyperresponsiveness 48 neoadjuvant chemotherapy 48 XGEVA 48 pharmacokinetic pharmacodynamic 48 univariate 48 ORENCIA ® 48 Aflibercept 48 acromegalic patients 48 μg dose 48 PRECiSE 48 ALT elevations 48 CrCl 48 mean baseline HbA1c 48 non splenectomized 48 prospective randomized controlled 48 IIa trial 48 gemcitabine 48 serum HBV DNA 48 symptomatic BPH 48 acute gout flares 48 eszopiclone 48 lymphocyte counts 48 multivariate adjustment 48 nonmetastatic prostate cancer 48 -#.# ± [002] 48 fluticasone 48 gemcitabine carboplatin 48 events TEAEs 48 Bezielle 48 #μg [002] 48 cardiovascular calcification 48 Tolerability 48 paraprotein 48 pharmacokinetic 48 nocturnal hypoglycaemia 48 inert placebo 48 olmesartan 48 aminotransferase elevations greater 48 #.#g/day 48 Postoperative 48 pharmacokinetic PK study 48 preoperatively 48 neoadjuvant 48 mg BID dose 48 C1 INH 48 linaclotide treated 48 QTc intervals 48 oral allopurinol 48 oxcarbazepine 48 eltrombopag 48 lamotrigine 48 nmol liter 48 pyridostigmine 48 radiographic progression 48 multivariate Cox 48 ± SD 48 specific antigen PSA 48 velafermin 48 fractional shortening 48 oral glucose tolerance 48 acutely decompensated congestive heart 48 idiopathic Parkinson disease 48 liposomal doxorubicin 48 mg tid 48 meta regression 48 Median survival 48 lubiprostone 48 sirolimus eluting stent 48 nonfatal MI 48 subcutaneous dose 48 riociguat 48 Teriflunomide 48 mcg kg REBETOL 48 Tarceva TM 48 Acute Ischemic Stroke 48 left ventricular diastolic 48 TAXUS ATLAS 48 normotensive 48 blinded randomized 48 ng dL 48 primary hypercholesterolemia 48 pharmacokinetic PK profile 48 nadroparin 48 HRQoL 48 canakinumab 48 sd = 48 Somnolence 48 PROactive study 48 fraction LVEF 48 PREZISTA ritonavir 48 visual acuity 48 SPIRIT FIRST 48 dose escalation phase 48 multicenter randomized controlled 48 -#.# mg dL [001] 48 opioid naïve 48 YERVOY 48 Non inferiority 48 beclomethasone dipropionate 48 hemostatic efficacy 48 ug dose 48 concomitant medications 48 daytime alertness 48 UPDRS scores 48 humanized interleukin 6 48 vinorelbine 48 pegaptanib 47 dose cytarabine 47 budesonide formoterol 47 serum testosterone 47 virologic suppression 47 imatinib 47 leukocyte count 47 erlotinib 47 Neuropsychiatric Inventory 47 mg doses 47 alanine aminotransferase 47 liver transaminases 47 genotypic resistance 47 cisplatin gemcitabine 47 intravenous diuretics 47 CHOP chemotherapy 47 glargine 47 cetuximab 47 GnRH agonist 47 doxorubicin cyclophosphamide 47 RSD# oral 47 bupropion SR 47 moderate hepatic impairment 47 sinus rhythm 47 Kepivance 47 NIS LL 47 L thyroxine 47 BPH symptom 47 Relapsing Remitting Multiple Sclerosis 47 guanfacine extended release 47 COPEGUS 47 mg/# hr 47 ORMD 47 adjunctive ABILIFY 47 isoproterenol 47 Kaplan Meier survival 47 EVIZON 47 ruboxistaurin 47 rolofylline 47 #.#/#.# mmHg [001] 47 valacyclovir 47 bezafibrate 47 salmeterol fluticasone propionate 47 ZOMIG Nasal Spray 47 EDEMA3 47 transient insomnia 47 pharmacokinetic PK